Why a women-focused comparison?

Two facts shape this page. First, the numbers: CDC/NCHS data for August 2021–August 2023 puts obesity prevalence at 41.3% among U.S. women, with severe obesity at 12.1% — notably higher than the 6.7% rate among men.

Second, the medical context differs. Pregnancy and fertility planning are hard exclusions for weight-loss medication, contraception questions interact with treatment decisions, and several telehealth programs now build their intake and care model specifically around women's health. That changes what "the best program" means.

What treatments are available?

The options for women are the same approved medications covered across this site, prescribed when a clinician confirms eligibility — obesity (BMI 30+), or overweight (BMI 27+) with a weight-related condition:

• GLP-1 injections — semaglutide (Wegovy), approved in 2021, and tirzepatide (Zepbound), approved in 2023, both once-weekly.
• Oral prescription options — including orlistat, phentermine-topiramate, and naltrexone-bupropion, per NIDDK's approved list.
• Coaching and lifestyle programs — with or without medication, often bundled by women-focused telehealth brands.

What results did women see in trials?

Women made up the majority of participants in the landmark trials — 67.5% of SURMOUNT-1's 2,539 enrollees, for example. The headline outcomes therefore describe largely female cohorts: average reductions of 14.9% at 68 weeks for semaglutide 2.4 mg in STEP 1, and 15.0% to 20.9% at 72 weeks across tirzepatide doses in SURMOUNT-1, both alongside lifestyle intervention.

As always, trial averages are not personal predictions — dose tolerance, adherence, and life stage all matter. But women considering these medications are not extrapolating from someone else's data; the evidence base is substantially built on women.

What should a women-focused program include?

Beyond the basics every good telehealth program needs — licensed clinician review, transparent pricing, pharmacy clarity, reachable support — look for the women-specific markers:

• Pregnancy and contraception screening built into the intake and repeated at refills.
• Clinicians comfortable with women's health — able to discuss cycles, perimenopause, and PCOS alongside weight treatment.
• A plan for life changes — clear guidance on what happens to treatment if you become pregnant or start trying.
• Support beyond the prescription — nutrition and habit coaching mirrors how these medications were actually studied.

Who may not be a good fit?

Skip prescription weight-loss treatment if you are pregnant, planning pregnancy, or breastfeeding. The FDA's tirzepatide warnings — personal or family history of medullary thyroid cancer or MEN2, unstudied in pancreatitis history — apply to women and men alike.

And if your goal is modest, or medication cost is the obstacle, a structured lifestyle program is a legitimate first move. NIDDK's framing holds: medication supports healthy eating and activity; it does not replace them.